• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Evonik

    Novo`s Amylin Injectable Cagrilintide Achieves 11.8% Weight Loss

    BIOSPACE

    Novo Nordisk Unveils Phase 3 Data for Amylin Cagrilintide

    GLOBENEWSWIRE

    Novo Nordisk to Unveil Semaglutide Data on `Food Noise`

    GLOBENEWSWIRE

    Novo Nordisk starts new CagriSema weightloss drug trial

    REUTERS

    ADA 2025: Novo Nordisk showcases new semaglutide data, redefining

    GLOBENEWSWIRE

    Novo trial with next-gen diabetes drug shows 15.7% weight loss

    REUTERS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.